Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, cross-over trial. On naproxen treatment, 52% of the patients had no severe headaches whereas 19% had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. Naproxen sodium can be recommended as a drug of first choice for migraine prevention.
Get full access to this article
View all access options for this article.
References
1.
CarlsonLAEkelundLGOroL. Clinical and metabolic effects of different doses of prostaglandin E1 in man. Acta Med Scand1968;183:423–30.
2.
WelchKMASpiraPJKnowlesL. Effects of prostaglandins on the internal and external carotid blood flow in the monkey. Neurology (Minn)1974;24:705–10.
3.
SkinhöjE. Hemodynamic studies within the brain during migraine. Arch Neurol1973;29:95–8.
4.
MoncadaSVaneJR. Unstable metabolites of arachidonic acid and their role in hacmostasis and thrombosis. Br Med Bull1978;34(2):129–35.
5.
HiltonBPCumingsJN. An assessment of platelet aggregation induced by 5-hvdroxytryptamine. J Clin Path1971;24:250.
6.
KalendovskyZAustinJH. Complicated migraine. Its association with increased platelet aggregability and abnormal plasma coagulation factors. Headache1975;15:18–35.
7.
CouchJRHassaneinRS. Platelet aggregability in migraine. Neurology1977;27:843–8.
8.
AnthonyMLanceJW. Indomethacin in migraine. Med J Aust1968;1:56–7.
9.
StensrudPSjaastadO. Clinical trial of a new antibradykinin, anti-inflammatory drug, ketoprofen (19,583 RP) in migraine prophylaxis. Headache1974;14:96–100.
10.
MaselBEChessonALAlperinJBLevinHSPetersBH. Clinical trial of platelet inhibition using aspirin and dipyridamole in migraine prophylaxis. Neurology1978;28:371.
11.
Ad Hoc Committee on Classification of Headache: Classification of headache.JAMA1962;179:717–18.
12.
KochGG. The use of non-parametric methods in the statistical analysis of the two-period changeover design. Biometrics1972:577–84.
13.
GartJJ. An exact test for comparing matched proportions in crossover designs. Biometrika1969:75–80.
14.
LindegaardKFØvrelidLSjaastadO. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache.1980;20:96–8.
15.
O'NeillBPMannJD. Aspirin prophylaxis in migraine. Lancet2, 1978;1179–81.
16.
VardiYRabeyIMStreiflerMSchwartzALindnerHRZorV. Migraine attacks: alleviation by an inhibitor of prostaglandin synthesis and action. Neurology1976;26:447–50.
17.
RabeyJMVardiYVan DyckDStreiflerM. Ophthalmologic migraine: amelioration by flufenamic acid. A prostaglandin inhibitor. Ophthalmologica (Basel),1977;175:148–52.
18.
HakkarainenHVapaatoloHGothoniGParanthainenJ. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet1979;326–8.
19.
WeberRBReinmuthOM. The treatment of migraine with propranalol. Neurology1972;22:366–9.
20.
DiamondSMedinaJL. Double blind study of propranolol for migraine prophylaxis. Headache1976;16:24–32.
